BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 12783905)

  • 1. Acetylcysteine and renal function following coronary angiographic procedures.
    Shen AY
    JAMA; 2003 Jun; 289(21):2794-5; author reply 2796. PubMed ID: 12783905
    [No Abstract]   [Full Text] [Related]  

  • 2. Acetylcysteine and renal function following coronary angiographic procedures.
    Bagshaw SM; Culleton BF
    JAMA; 2003 Jun; 289(21):2795; author reply 2796. PubMed ID: 12783908
    [No Abstract]   [Full Text] [Related]  

  • 3. Acetylcysteine and renal function following coronary angiographic procedures.
    Balderramo DC
    JAMA; 2003 Jun; 289(21):2795-6; author reply 2796. PubMed ID: 12783907
    [No Abstract]   [Full Text] [Related]  

  • 4. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial.
    Kay J; Chow WH; Chan TM; Lo SK; Kwok OH; Yip A; Fan K; Lee CH; Lam WF
    JAMA; 2003 Feb; 289(5):553-8. PubMed ID: 12578487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial).
    Diaz-Sandoval LJ; Kosowsky BD; Losordo DW
    Am J Cardiol; 2002 Feb; 89(3):356-8. PubMed ID: 11809444
    [No Abstract]   [Full Text] [Related]  

  • 6. Reno-protective effect of N-acetyl cysteine in patients with impaired renal function undergoing coronary angiography and interventions.
    Ramesh N; Pillai RK; Abraham T; Padmaja NP; Hameed S; Vijayaraghavan G
    J Assoc Physicians India; 2006 Jun; 54():449-52. PubMed ID: 16909692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Does N-acetylcysteine prevent contrast-induced nephropathy?
    Vaitkus PT
    Am J Cardiol; 2002 Dec; 90(12):1424; author reply 1424-5. PubMed ID: 12480065
    [No Abstract]   [Full Text] [Related]  

  • 8. N-acetylcysteine versus AScorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial.
    Jo SH; Koo BK; Park JS; Kang HJ; Kim YJ; Kim HL; Chae IH; Choi DJ; Sohn DW; Oh BH; Park YB; Choi YS; Kim HS
    Am Heart J; 2009 Mar; 157(3):576-83. PubMed ID: 19249432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of contrast nephropathy.
    Curhan GC
    JAMA; 2003 Feb; 289(5):606-8. PubMed ID: 12578494
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of contrast-induced nephropathy in patients undergoing emergent coronary procedures.
    Bouzas-Mosquera A; Vázquez-Rodríguez JM
    Am J Cardiol; 2008 Mar; 101(6):910. PubMed ID: 18328863
    [No Abstract]   [Full Text] [Related]  

  • 11. Contrast loaded with N-acetylcysteine for coronary imaging during percutaneous coronary intervention: a new concept for renal and myocardial protection during percutaneous coronary intervention.
    Fischell TA
    JACC Cardiovasc Interv; 2009 Mar; 2(3):222-3. PubMed ID: 19463429
    [No Abstract]   [Full Text] [Related]  

  • 12. Efficacy of N-acetylcysteine and hydration versus placebo and hydration in decreasing contrast-induced renal dysfunction in patients undergoing coronary angiography with or without concomitant percutaneous coronary intervention.
    Seyon RA; Jensen LA; Ferguson IA; Williams RG
    Heart Lung; 2007; 36(3):195-204. PubMed ID: 17509426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of N-acetylcysteine on cystatin C-based renal function after elective coronary angiography (ENABLE Study): a prospective, randomized trial.
    Kim BJ; Sung KC; Kim BS; Kang JH; Lee KB; Kim H; Lee MH
    Int J Cardiol; 2010 Feb; 138(3):239-45. PubMed ID: 18793808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N-acetylcysteine does not prevent renal dysfunction after off-pump coronary artery bypass surgery.
    Prasad A; Banakal S; Muralidhar K
    Eur J Anaesthesiol; 2010 Nov; 27(11):973-7. PubMed ID: 20299984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous N-acetylcysteine in the prevention of contrast media-induced nephropathy.
    Anderson SM; Park ZH; Patel RV
    Ann Pharmacother; 2011 Jan; 45(1):101-7. PubMed ID: 21205947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nephrotoxicity of contrast media and protective effects of acetylcysteine.
    Briguori C; Quintavalle C; De Micco F; Condorelli G
    Arch Toxicol; 2011 Mar; 85(3):165-73. PubMed ID: 21140133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral acetylcysteine as an adjunct to saline hydration for the prevention of contrast-induced nephropathy following coronary angiography. A randomized controlled trial and review of the current literature.
    Goldenberg I; Shechter M; Matetzky S; Jonas M; Adam M; Pres H; Elian D; Agranat O; Schwammenthal E; Guetta V
    Eur Heart J; 2004 Feb; 25(3):212-8. PubMed ID: 14972421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acetylcysteine in the prevention of contrast-induced nephropathy after coronary angiography.
    Oldemeyer JB; Biddle WP; Wurdeman RL; Mooss AN; Cichowski E; Hilleman DE
    Am Heart J; 2003 Dec; 146(6):E23. PubMed ID: 14661012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of N-acetylcysteine, theophylline or bicarbonate on contrast-induced rat renal vasoconstriction.
    Efrati S; Berman S; Ilgiyeav I; Siman-Tov Y; Averbukh Z; Weissgarten J
    Am J Nephrol; 2009; 29(3):181-91. PubMed ID: 18781062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preventive strategies of renal insufficiency in patients with diabetes undergoing intervention or arteriography (the PREVENT Trial).
    Lee SW; Kim WJ; Kim YH; Park SW; Park DW; Yun SC; Lee JY; Kang SJ; Lee CW; Lee JH; Choi SW; Seong IW; Suh J; Cho YH; Lee NH; Cheong SS; Yoo SY; Lee BK; Lee SG; Hyon MS; Shin WY; Lee SW; Jang JS; Park SJ
    Am J Cardiol; 2011 May; 107(10):1447-52. PubMed ID: 21420063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.